What is the treatment of choice for thrombotic thrombocytopenic purpura (TTP)?

What is the treatment of choice for thrombotic thrombocytopenic purpura (TTP)?

• A. Platelet transfusion
• B. IV iron
• C. Vitamin K
• D. Plasmapheresis is treatment of choice

Answer: (D)

Thrombotic thrombocytopenic purpura involves widespread microthrombi caused by severe ADAMTS13 deficiency, leading to platelet consumption and hemolysis. The treatment of choice is therapeutic plasma exchange (plasmapheresis) because it rapidly removes the autoantibodies against ADAMTS13 and provides functional ADAMTS13, stopping new microthrombi from forming and reversing the thrombocytopenia and hemolysis. Platelet transfusion is not the primary therapy and can worsen microthrombi by adding more platelets to the clots, so it’s usually avoided unless there is life-threatening bleeding. Vitamin K and IV iron do not address the underlying ADAMTS13 deficiency or the thrombotic process. Adjunctive therapies, such as corticosteroids, may be used especially if an immune-mediated mechanism is suspected, and rituximab can be considered in refractory cases. Starting plasmapheresis promptly is essential, as delays increase mortality.

Thrombotic thrombocytopenic purpura involves widespread microthrombi caused by severe ADAMTS13 deficiency, leading to platelet consumption and hemolysis. The treatment of choice is therapeutic plasma exchange (plasmapheresis) because it rapidly removes the autoantibodies against ADAMTS13 and provides functional ADAMTS13, stopping new microthrombi from forming and reversing the thrombocytopenia and hemolysis. Platelet transfusion is not the primary therapy and can worsen microthrombi by adding more platelets to the clots, so it’s usually avoided unless there is life-threatening bleeding. Vitamin K and IV iron do not address the underlying ADAMTS13 deficiency or the thrombotic process. Adjunctive therapies, such as corticosteroids, may be used especially if an immune-mediated mechanism is suspected, and rituximab can be considered in refractory cases. Starting plasmapheresis promptly is essential, as delays increase mortality.